Posts

FDA’s speedy voucher program reportedly shelved, but HHS says pilot is ongoing

on
A Reuters report dated November 12 says the FDA has effectively shelved the Commissioner’s National Priority Voucher (CNPV) pilot, launched in 2025 under former Commissioner Marty Makary to accelerate selected drug reviews to as little as one or two months. According to Reuters’ six sources and internal documents, no new vouchers have been awarded since Makary left in May, the political-appointee executive council overseeing the program has gone dormant, and companies’ new applications reportedly are not advancing. The program’s status is disputed: an HHS spokesperson says the pilot is ongoing while the FDA reviews feedback from a June public hearing and considers how to refine it. There has been no formal announcement terminating the program. The report concerns this specific commissioner-led pilot—not every FDA expedited-review pathway. Existing voucher recipients may still be undergoing reviews. Sources: EXCLUSIVE: US FDA shelves commissioner's voucher program for sp...

Vir Biotechnology prices $150 million stock offering

on

Unlearn and Structure to explore AI digital twins in obesity study

on

Q3 2026 earnings-season losers: sharp drops and disappointing outlooks

on

Astellas and Immuneering plan two pancreatic cancer studies

on

FDA reportedly shelves speedy drug-review voucher program

on

Study finds drug ads can sway AI treatment recommendations

on

Alterra Labs raises $12.5 million to test and improve healthcare AI

on

Google Cloud launches Gemini for healthcare

on

Beeline reports positive Phase 2 results for lupus drug afimetoran

on

Neurosterix raises $105 million to advance schizophrenia drug

on

Blackstone to fund up to $1.5 billion of Pfizer’s berobenatide development

on

Analysis: Raising German drug prices could raise costs on both sides

on